Literature DB >> 15880315

Antibiotic use and the risk of flare of inflammatory bowel disease.

Faten N Aberra1, Colleen M Brensinger, Warren B Bilker, Gary R Lichtenstein, James D Lewis.   

Abstract

BACKGROUND & AIMS: Intestinal microbial flora participate in the pathogenesis of inflammatory bowel disease. Because antibiotic therapy alters intestinal microbial flora, we hypothesized that use of antibiotics might decrease the risk of flare.
METHODS: We conducted a case-crossover study by using the General Practice Research Database from 1989-1997. Flares of disease were identified by receipt of a new prescription for either corticosteroids or mesalamine medications after an interval of at least 4 months without prescriptions for either class of medication. The primary exposure was receipt of any antibiotics in the 60 days preceding the index date.
RESULTS: Among 1205 patients with Crohn's disease, exposure to antibiotics was associated with a reduced risk of flare (adjusted odds ratio [OR], 0.78; 95% confidence interval [CI], 0.64-0.96; P = .019). The effect was strongest with more recent exposure (test for trend, P < .05). Among 2230 patients with ulcerative colitis, use of any antibiotics within 60 days was not associated with flare of disease (adjusted OR, 0.96; 95% CI, 0.82-1.12; P = .581), although a potentially protective effect was observed in those patients with very recent exposure (exposure within 15 days: OR, 0.66; 95% CI, 0.51-0.85).
CONCLUSIONS: Antibiotic use within 60 days was associated with a lower risk of flare of Crohn's disease, but not ulcerative colitis. The strength of the protective effect of antibiotics in Crohn's disease wanes over time.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15880315     DOI: 10.1016/s1542-3565(05)00020-0

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  13 in total

1.  Thiazolidinedione use and ulcerative colitis-related flares: an exploratory analysis of administrative data.

Authors:  Jennifer L Lund; Til Stürmer; Carol Q Porter; Robert S Sandler; Michael D Kappelman
Journal:  Inflamm Bowel Dis       Date:  2011-03       Impact factor: 5.325

2.  [New therapeutic approaches to special diseases of the small intestine].

Authors:  M Schumann; K Herrlinger; M Zeitz; E F Stange
Journal:  Internist (Berl)       Date:  2010-06       Impact factor: 0.743

Review 3.  A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections.

Authors:  Alan Ebringer; Taha Rashid; Harmale Tiwana; Clyde Wilson
Journal:  Clin Rheumatol       Date:  2006-08-29       Impact factor: 2.980

Review 4.  Environmental factors in the relapse and recurrence of inflammatory bowel disease: a review of the literature.

Authors:  Thomas D Martin; Simon S M Chan; Andrew R Hart
Journal:  Dig Dis Sci       Date:  2014-11-19       Impact factor: 3.199

5.  Case-control study of factors that trigger inflammatory bowel disease flares.

Authors:  Linda A Feagins; Ramiz Iqbal; Stuart J Spechler
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 6.  Methods to control for unmeasured confounding in pharmacoepidemiology: an overview.

Authors:  Md Jamal Uddin; Rolf H H Groenwold; Mohammed Sanni Ali; Anthonius de Boer; Kit C B Roes; Muhammad A B Chowdhury; Olaf H Klungel
Journal:  Int J Clin Pharm       Date:  2016-04-18

7.  Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity.

Authors:  Ira Shafran; Patricia Burgunder
Journal:  Dig Dis Sci       Date:  2010-01-29       Impact factor: 3.199

8.  ACG Clinical Guideline: Management of Crohn's Disease in Adults.

Authors:  Gary R Lichtenstein; Edward V Loftus; Kim L Isaacs; Miguel D Regueiro; Lauren B Gerson; Bruce E Sands
Journal:  Am J Gastroenterol       Date:  2018-03-27       Impact factor: 10.864

Review 9.  Antibiotics and probiotics in inflammatory bowel disease: when to use them?

Authors:  Bincy Abraham; Eamonn M M Quigley
Journal:  Frontline Gastroenterol       Date:  2019-03-22

10.  Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.

Authors:  Mariam Molokhia; Paul McKeigue; Vasa Curcin; Azeem Majeed
Journal:  PLoS One       Date:  2008-06-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.